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ABSTRACT  
We have developed recombinant wild type and mutant 
human interferon α2b (rhIFNα2b) from synthetic gene in 
Escherichia coli. To identify the successful product of the proteins, 
immunology-based assay was suggested due to specificity for 
characterization. This work was aimed to develop and characterize 
rhIFNα2b polyclonal antibody generated in White New Zealand 
rabbits. The rhIFNα2b was overproduced in Escherichia coli BL21 
containing rhIFNα2b synthetic gene in pET32b.The protein was 
obtained as inclusion bodies, refolded, purified using nickel affinity 
chromatography, and characterized using polyacrylamide gel 
electrophoresis. The purified rhIFNα2b protein was injected into 
rabbits for 21 days. Absorption of E.coli antibody was done using 
total E. coli protein to remove antibody againts host cell.   The 
generation of antibody was monitored using dot blot and Western 
blot methods and quantified using Enzyme Linked Immunsorbant 
Assay (ELISA). To do so, rhIFN2b was used as an antigen. The 
result showed that the rhIFNα2b was produced as a His-tag protein 
fusion of 33kDa in size. The results of dot blot and Western blot 
analyses strongly indicated that antibody against rhIFNα2b was 
generated and specifically recognized rhIFNα2b. ELISA showed that 
the titer of the polyclonal anti-rhIFNα2b was 1:10.000. In 
conclusion, polyclonal antibody spesifically against rhIFNα2b protein 
was successfully detected with high titer after 21 days after rabbit 
immunization. 
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INTRODUCTION 
Interferon (IFN) is an endogenous 
cytokine generated as a response to virus, 
parasites, and mitogen. Based on its receptor, 
IFN is classified into type I (primary secreted 
by leukocytes and fibroblast) and type II 
(mainly produced by T-cells). IFN type I 
consists of IFNα, IFNβ, IFNκ, and IFNτ, while 
type II consists of IFNγ [Baldarrain et al.¸ 
2001]. Currently, IFN has been developed for 
antiviral and anticancer treatments. However, 
the therapeutic use of IFN limited clinical 
application due to its short biological half life, 
its protease instability, and other side effects 
(Jonasch and Halusca, 2001; Thitinan and 
McConville, 2009).  
IFNα2b is the mostly studied of IFN 
type I. It has been approved by World Health 
Organization for therapeutic use against 
hepatitis B and C virus infections. In our 
previous research, recombinant human  
IFNα2b (rhIFNα2b) coding region was 
synthesized using Thermodynamically Balanced 
Inside-Out method. An Escherichia coli           
BL21 carrying pET32b inserted by the 
rhIFNα2b coding region was used to produce 
rhIFNα2b. The rhIFNα2b was successfully 
purified and characterized (Retnoningrum et.al., 
2010).  
Polyclonal antibody has been widely 
used in immunoassay, especially in research and 
clinical laboratories. Polyclonal antibody has 
wide application such as immunoblotting and 
immunostaining to identify and characterize 
antigens. It is also used for characterization of 
engineered protein and immunoprecipitation. 
Polyclonal antibody is commonly generated 
from immunized animals:rabbit, rat, mice, and 
horse. In the laboratory scale, rabbit is generally 
used because of its size, its easiness in handling, 
Heny Rachmawati 
Volume 25 Issue 3 (2014) 133 
and its ability to generate higher amount of 
antibody as compared to rat or mouse (Asai, 
1993). 
We reported here the successful 
development of antibody anti-rhifnα2b in White 
New Zealand rabbit. Our established rhifnα2b 
was used as an antibody inducer as well as to 
detect the antibody generation both 
qualitatively and quantitatively. 
 
MATERIAL AND METHODS 
Microorganism animal and growth 
medium 
Escherichia coli harboring pET32b IFNα2b 
(E. Coli pET32b IFNα2b) was constructed in 
our previous work and was used as a source to 
obtain rhIFNα2b protein. Rabbit strain White 
New Zealand (12 weeks, 2 kg, female and male) 
was obtained from PT Bio Farma (Persero, 
Bandung, Indonesia). Luria Bertani agar and 
broth containing 100μg/mL ampicillin was 
used to growth recombinant E. coli.  
 
Protein overproduction, purification and 
characterization.  
E. coli pET32b IFNα2b was inoculated 
in 30mL of Luria Bertani (LB) liquid medium 
containing100μg/mL ampicillin (Sigma, New 
York, USA). The growth of the bacteria was 
done at 37°C, 150 rotation per minutes (rpm) 
for 16h with rigorous shaking. 5% (v/v) of  16-
hour inoculum was added into 320mL of LB 
broth containing 100μg/mL ampicillin  for 3 
hours. Culture was induced at OD600 ~ 0.5 
using 0.5mM isopropyl β-D-1-thiogalacto-
pyranoside (IPTG, Sigma) and culture was 
incubated for additional 3 hours in the same 
condition. Cells were collected by centrifuga-
tion at 1.300x g for 15min. The pellet was 
washed in 6mL of binding buffer without 
imidazole containing  1mM of phenyl-methyl-
sulphonyl fluoride (PMSF, Sigma). The cells 
were disrupted by sonication at 4MHz for 
10min. Cells were sonicated for 30s and then 
allowed to cool down for another 30s on ice. 
Suspension was centrifuged at 5.000x g for 
15min. Most of the rhIFNα2b protein was 
produced as inclusion bodies (IB) and  refolded 
in 6M urea for 60min. Soluble rhIFNα2b was 
obtained by centrifugation at 5.000x g for 
30min.  
Nickel affinity chromatography was used 
to purify rhIFNα2b according to manufacturer 
(Novagene). 5mL of total protein of 256μg/mL 
was loaded and eluted protein was collected in 
6 fractions. Purified rhIFNα2b protein was 
measured using Bradford method. Total and 
purified proteins were characterized by 15% 
Sodium Dudocyl Sulphate Polyacrylamide  Gel 
Eelectrophoresis (SDS-PAGE). 20μL of 
sampel protein from 6 fraction of purified 
protein (5.12μg; 5.64μg; 6.1μg; 3.40μg; 1.68μg) 
were mixed with 5μL of sample buffer. 
Electrophoresis was done at 125V for 60min.  
 
Generation of polyclonal antibody in 
rabbit. 
Purified rhIFNα2b was sterilized with 
0.22 micron filter.Concentration of protein was 
measured with Bradford method. The sterilized 
rhIFNα2b was used to immunize 2 different 
rabbits (2.5 kg, 3 months, and specific pathogen 
free) subcutaneously at five spots on the back 
site of the animals. The first immunization was 
conducted using1 mL of solution I containing 
100μg purified rhIFNα2b protein in 0.5mL of 
elute buffer and 0.5mL complete Freud 
adjuvant. Reimmunization was done three 
times with 1mL of solution II containing 200μg 
purified rhIFNα2b protein  in 0.5mL of elute 
buffer and 0.5mL incomplete Freud adjuvant in 
14days interval. Blood was collected 10days 
after each immunization and then incubated at 
37°C for an hour.  Serum was obtained after 
centrifugation at 900 x g for 10min and then 
was stored at -20°C until used. 
 
Adsorption experiment.  
This step was aimed to adsorp antibodies 
againts E. coli BL21 total proteins in rabbit 
serum after immunization. Protein totals of E. 
coli was obtained from E. coli BL21 grown in 
50mL of  LB broth. Cell pellet was disrupted 
with sonication and total proteins were 
separated by centrifugation at 124x g for 
15min. Rabbit serum was mixed with total 
protein (256 μg/mL) at 7 (v/v) ratios,  1: 1.50; 
1: 1.75; 1: 2.00; 1: 2.25; 1: 2.50; 1: 2.75; and 1: 
3.00. The mixtures were incubated at room 
temperature for 30min and centrifuged at 966 x 
g for 2min. Supernatants were collected and 
stored at -20°C. 
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Characterization of polyclonal antibody.  
Dot blot, Western blot and ELISA were 
used to characterize the antibody. In dot blot 
method, 1.2μg of purified rhIFNα2b protein 
was blotted onto nitrocellulose membrane. 
Alkaline phosphatase-conjugated rat anti-rabbit 
IgG and elute buffer were used as positive and 
negative controls, respectively. Blocking of 
unspecific proteins was done by incubating 
nitrocellulose membrane in Phospate Buffer 
Saline (PBS) containing 5% (w/v) of skim milk 
at room temperature for 60 min with gentle 
shaking. The membrane was then washed 3 
times  with TBST [0.1% (v/v) of Tween in Tris 
Buffer Saline (TBS)] then incubated with rabbit 
serum (dilution 1:2,500 using PBS containing 
5% skim milk and 0.1% tween) at 4°C for two 
hours. The washing  step was repeated 3 times 
with the same condition. The membrane was 
incubated with alkaline phospatase-conjugated 
rat anti-rabbit IgG (dilution 1:10,000 in TBS 
containing 5% skim milk and 0.1% tween) at 
room temperature for an hour and then 
washed. The staining was developed by 
incubation in 33μL of Nitro Blue Tetrazolium 
Chloride (NBT, Sigma, 50 mg/mL)] and 66μL 
of 5-Bromo-4-chloro-3-indolyl phosphate 
(BCIP, Sigma, 50mg/mL) in 10mL alkaline 
phospatase solution (100 mM sodium chloride; 
5mM MgCl2; 100mL trisHCl, pH 9.5) at dark 
room for 15min. Reaction was stopped by 
soaking membrane in 20mM EDTA solution. 
 
Western blot.  
The gel containing protein (5.12μg and 
5.64μg) was transblotted onto nitrocellulose 
membrane in 1L transfer buffer [2.2g glycine; 
5.8g tris base; 0.37g SDS; 200mL methanol 
(v/v); add aquadest up to 1L, pH 7,4] at 90Volt 
for 90min. Nitrocellulose membrane was 
treated with the same procedure for dot blot. 
 
ELISA.  
0.5ng/uL of purified  rhIFNα2b in PBS 
was loaded into microtiter plate. The plate was 
incubated at 4°C overnight and washed with 
200μL of PBST twice and 200μL of TBS once 
for each well. Blocking of unspecific binding 
was done  with 5% of skim milk in PBS at 
room temperature for 60min. The plate was 
washed, incubated with rabbit’s serum (dilution 
1:1000-1:10.000) for an hour and washed again. 
Plate was incubated with 200μL alkaline 
phosphatase-conjugate rat anti-rabbit IgG 
(dilution 1:5000 in  PBS) at 37°C for 60min and 
washed. The yellow color were developed by 
adding 200μL of PNPP  (1mg/mL in 10% 
dietanolamin) into each well. The plate was 
incubated at 37°C for an hour. The adsorption 
was read by ELISA-reader (BioRad) at 405nm. 
 
RESULT AND DISCUSSION 
Recombinant human IFNα2b over-
production and purification. 
The amount of protein (total protein of  
E. coli, rhIFNα2b IB, and purified rhIFNα2b) 
(Table I). The result of SDS-PAGE methods 
for E. coli pET32b IFNα2b total soluble 
proteins from induced condition (Figure 1). 
Thick bands of 33 kDa (theoretical size of 
protein fusion of rhIFNα2b) were observed 
which are indicating the correct protein. 
 
Table I. Total Protein and Product yield  
 
Fraction Volume 
(mL) 
Total 
protein 
(μg) 
Product 
Yield(%) 
E.coli 
pET32b 
IFNα2b’s 
total protein 
320 3.073 100 
IB  12 1.686  55 
Purified IB    6 1.060  34 
 
 
 
Figure 1.  Coomassie briliant blue-stained 15% 
SDS–PAGE of protein overproduction and 
purification. 1 = protein marker, 2 = E. coli 
total soluble proteins from induced condition, 3 
=  refolded protein, 4 = purified rhIFNα2b 
from total refolded protein. 
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Figure 2. Dot blot of preimmune, immune and adsorbed rabbit sera. (A) Preimmune and immune 
sera. 1 = rat anti-rabbit IgG alkaline phosphate (positive control), 2 = elute buffer (negative 
control), 3 = 1.2 ng of purifiedrhIFNα2b, 4 = 0.645ng of purifiedrhIFNα2b, 5 = E .coli BL21 total 
protein. (B) Serum from female rabbit , (C) serum from male rabbit . 1 = 1.28μgof purified 
rhIFNα2b and E. coli BL21 total protein, 2 = 1.2μg purified rhIFNα2b (positive control), 3 = elute 
buffer (negative control), 4 =ratio  volume of rabbit sera to E. Coli BL21 total protein. 
 
 
 
Figure 3. Characterization of rabbit sera by Western blot analysis using purified rhIFNα2b. 15% 
SDS-PAGE (A),Western blots of sera from female (B) and male (C) rabbits. 1 = marker protein, 2 
= 4.2µg of purified rhIFNα2b from IB, 3 = 3.4µg of purified rhIFNα2b from supernatant. 
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             The  rhIFNα2b protein which is 
expressed in E. coli mostly will form  inclusion 
bodies (IB) and only a little was obtained from 
cytoplasm [Srivastava et al., 2005]. rhIFNα2b 
protein as IB can be refolded by 6 M urea 
[Tsumoto, Ejima, and Kumagai, 2003]. 
rhIFNα2b protein from cytoplasm did not used 
because the concentration was too low. 
 
Production of polyclonal anti-
recombinant human IFNα2b.  
Dot blot result from serum before 
immunization and after 10 days of the first 
immunization are shown in figure 2. No 
positive colour was produced from serum taken 
before immunization, indicating no antibody 
produced yet.In contrast, serum taken after 10 
days of the first immunization showed positive 
result for both female and male rabbit’s sera. In 
order to remove the antibodies against E.coli, 
the adsorption of anti-total protein was done at 
various concentrations. The optimum adsorption 
from female rabbit’s serum was 1:3.00, while 
the male rabbit’s serum was 1:2.25 (no colour 
produced at those ratios).Dot blot results from 
adsorption anti-total protein of E.coli BL21 are 
shown in figure 2. 
 
Polyclonal anti-recombinant human 
IFNα2b characterization.  
The antibody produced was analyzed 
semi quantitatively with Western blot which is a 
specific method. Western blot analyses are 
shown in figure 3. Purified rhIFNα2b were run 
at 15% SDS-PAGE. These membranes (Figure 
3.B and C) show thick and single purple bands 
at 33 kDa. The result of molecular  weight by 
SDS PAGE was shown as a 33 kDa band. 
Theoritically, the size of human IFNα2b 
protein is 19 kDa. From our previous research,  
rhIFNα2b protein was generated as fusion 
protein with 33 kDa in size. This additional size 
was originated from pET32b expression vector 
(Retnoningrum, et. al., 2010). The purpose of 
constructing the fusion protein containing six 
histidine amino acid was for purification using 
nickel affinity chromatography. 
The proteins were transferred to 
nitrocellulose membrane. The nitrocellulose 
membranes, figure 3, show bands at 33 kDa 
 
 
Figure 4.Titer assay of adsorbed polyclonal antibody against rhIFNα2b using ELISA.(▲) female 
rabbit serum without rhIFNα2b, (♦) male rabbit serum without rhIFNα2b, (■) male rabbit serum 
with 100 ngpurifiedrhIFNα2b; (●) female rabbit’s serum with 100 ng purified rhIFNα2b. 
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confirming the presence of anti-rhIFNα2b in 
rabbit’s serum. The result from Western blot 
showed that anti-rhIFNα2b recognized 
rhIFNα2b. A single band at 33 kDa, means that 
adsorption of anti-total protein of E. coli was 
optimum. 
ELISA was used to determine antibody 
titer in female and male rabbit’s serum. To find 
out the influence of serum dilution, a serial 
dilution of serum was made (1:1000-1:10.000) 
without addition of rhIFNα2b. The result from 
this can be seen at Figure 4 and showed that 
the serum dilution did not have any influence in 
ELISA. The titer of both female and male 
rabbit’s serum was 1:10.000. Absorbance from 
female rabbit’s serum was higher than male. 
Generally, female mammalian generates higher 
antibody than male. This caused by esterogen 
hormone in female that increases inflammation 
response and antigen presenting process to T 
and B cells [Bilbo and Nelson, 2001]. The 
findings we reported here is meaningful in the 
area of analytical method in particular for 
detection of rhifnα2b. This protein is routinely 
produced in our laboratory for many purposes 
such as to study the pharmacokinetic profile, 
activity study in various model of immune-
related diseases. As rhifnα2b is a potent 
therapeutic protein for many chronic diseases, 
the successful production of this 
macromolecules confirmed by immunology 
based-analysis such as Western blot and ELISA 
opens way to explore more about potential 
function of rhifnα2b as a drug. 
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CONCLUSION 
rhIFNα2b protein was successfully 
overproduced from E. coli pET32b IFNα2b. 
The protein was refolded and purified with 
nickel affinity chromatography. Purified 
rhIFNα2b protein was used to generate 
rhIFNα2b polyclonal antibody in New Zealand 
white rabbits. Polyclonal antibody was 
successfully generated confirmed with dot blot 
analysis.This antibody recognized protein at 33 
kD, i.e the size of rhIFN2b. Using protocol 
we developed, antibody was generated with 
high titer of 1:10,000 measured with ELISA.  
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